Patients en hémodialyse : l’incidence de cancer est-elle différente entre les diabétiques de type 2 comparés aux non-diabétiques ? Une étude du registre REIN

Background and objectivesIn France, diabetes mellitus is now the second cause of end stage renal disease. In a large previous French national study, we observed that dialyzed diabetics have a significant lower risk of death by cancer. This first study was focused on cancer death but did not investigate cancer incidence. In this context, the aim of this second study was to compare the incidence of cancer in diabetic dialyzed patients compared to non-diabetic dialyzed patients in a French region.MethodsThis epidemiologic multicentric study included 588 diabetic and non-diabetic patients starting hemodialysis between 2002 and 2007 in Bretagne. Data were issued from REIN registry and cancer incidence were individually collected from medical records. Diabetics and non-diabetics were matched one by one on age, sex and year of dialysis initiation.ResultsDuring the follow-up, we observed 28 cancers (9.4%) in diabetic patients and 26 cancers (8.9%) in non-diabetics patients. The cumulative incidence to develop a cancer 2 years after the dialysis start was approximately 6% in both diabetics and non-diabetics patients. In univariate Fine and Gray analysis, BMI, hemoglobin, statin use had P-value < 0.2. However, in the adjusted model, these variables were not significantly associated with cancer incidence.ConclusionThis study lead on a little number of dialyzed patients did not show any significant difference on cancer incidence between diabetic and non-diabetic patients after hemodialysis start.     

Different Risk Factors and Causes for Early Death after Initiating Dialysis in Diabetic and Non-Diabetic Patients

The mortality of patients with end-stage renal disease (ESRD) is especially high after the start of dialysis therapy, especially in diabetic patients. A part of these patients die within three months after initiating renal replacement therapy (RRT). In the present retrospective study we evaluated all patients with ESRD requiring RRT who died within 3 months after initiating the first RRT. A total of 42 patients who died such early after the start of dialysis treatment during the years 1995–2001 were included in the study. Of them, 28 subjects (age 66 + 11 years) were diabetics and 14 non-diabetics (age 76 + 10 years). Indications for the start of dialysis were end-stage renal failure (creatinine clearance < 10–12 mL/min or < 12–14 mL/min in diabetic patients) or fluid lung associated with chronic renal failure (creatinine clearance < 20 mL/min). Hyperhydration with fluid lung was the most common indication for dialysis therapy in patients with diabetes (64.3% versus 14.3%, p < 0.05). The vascular risk factors blood pressure and serum-lipids were similar in both groups; however, diabetic patients were younger than non-diabetic subjects. The prevalence of vascular diseases tended to be higher in the diabetic group, but difference was not significant (see ). Severe heart failure (NYHA stage III-IV) was more common among diabetics (42.8% versus 14.3%, p < 0.05). The incidence of sepsis (17.9% versus 14.3%) did not significantly differ between the groups. The most common cause of death was cardiovascular events in both diabetic and non-diabetic patients (71.5% and 64.2%, respectively). Heart failure was a more common cause of death in diabetic patients (39.2% versus 21.4%, NS). In conclusion, early death after the initiation of dialysis treatment was more common in patients with type 2 diabetes, though, the diabetic patients were less old. In the diabetic group fluid lung was more often indication for initiating dialysis therapy than in the non-diabetic group. In both, diabetic and non-diabetic patients, the most common causes of death are cardiovascular events.     

High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes

A randomized trial had suggested that high doses of erythropoiesis-stimulating agents (ESAs) might increase the risk of cardiovascular outcomes in predialysis diabetic patients. To evaluate this risk in diabetic patients receiving dialysis, we used data from 35,593 elderly Medicare patients on hemodialysis in the US Renal Data System of whom 19,034 were diabetic. A pooled logistic model was used to estimate the monthly probability of mortality and a composite cardiovascular end point. Inverse probability weighting was used to adjust for measured time-dependent confounding by indication, estimated separately for diabetic and non-diabetic cohorts. The adjusted 9-month mortality risk, significantly different between an ESA dose of 45,000 and 15,000?U/week, was 13% among diabetics and 5% among non-diabetics. In diabetic patients, the hazard ratio (HR) for more than 40,000?U/week was 1.32 for all-cause mortality and 1.26 for a composite end point of death and cardiovascular events compared with patients receiving 20,000 to 30,000?U/week. The corresponding HRs in non-diabetic patients were 1.06 and 1.10, respectively. A smaller effect of dose was found in non-diabetic patients. Thus, higher ESA doses, which are often necessary to achieve high hemoglobin levels, are not beneficial, and possibly harmful, to diabetic patients receiving dialysis. Our findings support a Food and Drug Administration advisory recommending that the lowest possible ESA dose be used to treat hemodialysis patients.     

Characteristics of the patients with diabetic nephropathy with relatively low serum creatinine at the initiation of dialysis

Clinical feature and creatinine metabolism were studied in 86 diabetic patients who had newly initiated dialysis treatment. In 32.5% of the patients, serum creatinine was below 8.0 mg/dl at the initiation of dialysis treatment. Gastrointestinal symptoms, general malaise, pulmonary edema and uremic encephalopathy were the causes which required dialysis treatment in those patients, and the frequency of pulmonary edema was significantly higher than in patients whose serum creatinine was above 8.0 mg/dl at the initiation of dialysis (p less than 0.05). There were no significant differences in serum urea nitrogen, potassium, sodium, albumin levels and hematocrit between low serum creatinine group (3.0-7.9 mg/dl) and high serum creatinine group (8.0-11.9 mg/dl) at the initiation of dialysis. Serum creatinine levels were highly correlated with creatinine generation rate (r = 0.788, p greater than 0.01). There was a significant correlation between creatinine generation rate and muscle volume (r = 0.863, p less than 0.001). Muscle volume of diabetic dialyzed patients was 29.5 +/- 7.0 cm3/cm in males and 26.9 +/- 5.0 cm3/cm in females, and those values were lower than those of non-diabetic dialyzed patients (p greater than 0.005). Frequency of the patients whose creatinine generation rate was below 1500 mg/day was 81.3% in diabetic hemodialyzed patients and this was significantly higher than in non-diabetic hemodialyzed patients (p less than 0.005). In conclusion, in patients with diabetic nephropathy who have to initiate dialysis treatment, uremic symptoms have progressed though serum creatinine levels are relatively low. This low serum creatinine levels in patients with diabetic end-stage renal disease are resulted from their low muscle volume.     

Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study

Secondary hyperparathyroidism is a frequent complication of long-term dialysis treatment, and despite recent advances in medical therapy, surgical parathyroidectomy (PTx) is necessary in a considerable number of uremic patients. A prevalence of PTx of 22% was reported in Europe in 1988 in patients on dialysis from 10 to 15 yr, but no large-scale epidemiologic study has been published since then. The aim of the study was to evaluate the prevalence, incidence, and risk factors for PTx in patients on renal replacement therapy (RRT) in Lombardy and to determine whether the incidence has changed over time. The study involved 14,180 patients included in the Lombardy Registry of Dialysis and Transplantation who received RRT for end-stage renal disease (ESRD) between 1983 and 1996. Cox-proportional hazards regression models were used to evaluate the risk factors of PTx, the explanatory covariates being age on admission to RRT, gender, underlying renal disease (nondiabetic or diabetic nephropathy), and dialysis modality (peritoneal dialysis or hemodialysis). The prevalence of PTx in the 7371 ERSD patients who were alive on December 31, 1996, was 5.5% and increased with the duration of RRT (9.2% after 10 to 15 yr, 20.8% after 16 to 20 yr). Similarly, the incidence of PTx increased from 3.3 per 1000 patient-years in patients who had been on RRT for <5 yr to 30 per 1000 patient-years in those receiving RRT for >10 yr. The Cox regression models showed that the relative risk for PTx was significantly higher in women and lower in elderly and diabetic patients. The relative risk for PTx (adjusted for gender, age, and nephropathy) was higher in the patients on peritoneal dialysis than in those on hemodialysis and decreased after transplantation. During the course of a follow-up of 7 yr, the incidence of PTx in patients who started RRT between 1990 and 1992 was no different from that observed in patients who started RRT between 1983 and 1985. In conclusion, the prevalence and incidence of PTx in patients receiving RRT in Lombardy is lower than that in Europe and Italy as a whole, as reported by the 1988 European Dialysis and Transplantation Association Registry; its frequency has not changed significantly during the past few years. The need for PTx decreases markedly after successful transplantation. The epidemiologic finding that the rate of PTx is greater in women, young patients, and individuals who do not have diabetes suggests the need for a more aggressive medical treatment of secondary hyperparathyroidism particularly in such patients.     

Coronary artery disease among diabetic and non-diabetic patients with end stage renal disease.

Cardiovascular disease is the major cause of death among patients with end stage renal disease and accounts for about half the deaths among the dialysis population. Several researchers have reported a high prevalence of coronary artery disease among diabetic patients with renal failure and coronary arteriography is often considered an integral part of the pre-transplant evaluation of diabetic patients with end stage renal disease. However, very few reports have addressed the question of coronary disease in non-diabetic patients, and the pattern and prevalence of coronary artery disease in non-diabetic patients with end stage renal disease are not well defined. We evaluated the clinical and coronary angiographic findings in 158 consecutive patients (84 diabetic and 74 non-diabetic) with end stage renal disease. The coronary arteries were divided into 16 segments and each segment was analyzed for the presence of coronary disease, which was defined as the presence of > or = 50% luminal diameter stenosis. Diabetic patients had more adverse risk factors for coronary artery disease, yet there was no significant difference in the prevalence of coronary artery disease between the diabetic and non-diabetic patients (67% vs. 55%, p = 0.15), or in the number of affected coronary artery segments (2.0 vs. 1.4, p = 0.05). Triple vessel coronary artery disease was however, significantly more common among the diabetic subjects (27% vs. 12%, p = 0.005). Non-diabetic patients with end stage renal disease also have a high prevalence of coronary artery disease and may merit as careful investigation of their coronary status as their diabetic counterparts.     

The diabetic patient: renal insufficiency like other kidney failures?

The number of patients requiring renal replacement therapy because of diabetic nephropathy has been relentlessly increasing, and diabetes mellitus is now the leading cause of end stage renal disease in most Western Countries. Diabetic nephropathy has specificities. First, it tends to progress rapidly toward end stage renal disease. Second, patients with diabetic nephropathy are at increased risk of cardiovascular disease, when compared to patients with non diabetic nephropathy; similarly to what has been shown for diabetic patients on dialysis. Third, patients with diabetic nephropathy tend to be more severely anemic than patients with non-diabetic chronic kidney disease. Finally, small studies suggest that patients with diabetic nephropathy could have lower serum concentrations of parathyroid hormone than patients with non-diabetic nephropathy and similar glomerular filtration rate.     

Discontinuation of treatment among Italian diabetic patients treated by renal replacement therapy

Death from dialysis termination has been extensively surveyedin Canada, the United States, and Australia. In the US old ageand the presence of diabetes has been associated with treatmentwithdrawal. On the other hand, information for Europe is veryscarce. We addressed the issue of dialysis termination in Italyin both a cohort of diabetic patients starting RRT in 1987,and two age-, sex-, type of RRT, and unit-matched cohorts ofdiabetic and non-diabetic patients alive on RRT treatment on31 December 1987. Follow-up was available till 31 December 1991.Dialysis termination accounted for 1.1% of the known causesof death in the incident diabetic cohort and for only 0.5% and0.9% of the prevalent diabetic and non-diabetic cohorts respectively.In Italy, diabetes is not associated with higher rates of dialysistermination and this cause of death seems uncommon among theoverall Italian RRT population. We cannot, however, excludea predialysis selection against patients presenting with anold age or comorbid conditions.     

Improved long-term survival rate of chronic dialysis patients with diabetes mellitus

Background. The survival rate of diabetic dialysis patients has been poor. However, it is uncertain whether the survival rate of these patients has been improving. Methods. Using the Okinawa Dialysis Study (OKIDS) registry, in which the records of all chronic dialysis patients in Okinawa, Japan, are filed, we compared the prognosis of dialysis patients with diabetes mellitus (DM) and that of dialysis patients with chronic glomerulonephritis (CGN). Using Cox proportional hazard analysis, we examined the effect of the start year of dialysis on survival after adjusting for confounding variables such as age, sex, and predialysis comorbid conditions. Results. Between 1976 and 1998, a total of 1256 DM patients and 2101 CGN patients started dialysis. In the DM patients who started dialysis between 1976 and 1990, the survival rate was 80.4% at 12 months and 42.1% at 60 months, and among those who started dialysis between 1991 and 1998, the survival rate was 87.9% at 12 months and 55.8% at 60 months. In both disease groups, the relative risk of death was significantly lower in patients who started dialysis between 1991 and 1998 than in those who started dialysis between 1976 and 1990. The adjusted relative risk (95% confidence interval [CI]) was 0.65 (95% CI 0.54–0.77). The relative risk of death of DM to CGN was 2.23 (95% CI, 1.91–2.60) when comparing those treated between 1976 and 1990, and 2.00 (95% CI, 1.62–2.46) when comparing those treated between 1991 and 1998. Conclusions. While the prognosis of diabetic dialysis patients in both categories improved significantly with time, that of DM patients was still worse than that of CGN patients. Received: December 14, 2000 / Accepted: March 29, 2001     

CORONARY ARTERY DISEASE AMONG DIABETIC AND NON-DIABETIC PATIENTS WITH END STAGE RENAL DISEASE

Cardiovascular disease is the major cause of death among patients with end stage renal disease and accounts for about half the deaths among the dialysis population. Several researchers have reported a high prevalence of coronary artery disease among diabetic patients with renal failure and coronary arteriography is often considered an integral part of the pretransplant evaluation of diabetic patients with end stage renal disease. However, very few reports have addressed the question of coronary disease in non-diabetic patients, and the pattern and prevalence of coronary artery disease in non-diabetic patients with end stage renal disease are not well defined. We evaluated the clinical and coronary angiographic findings in 158 consecutive patients (84 diabetic and 74 non-diabetic) with end stage renal disease. The coronary arteries were divided into 16 segments and each segment was analyzed for the presence of coronary disease, which was defined as the presence of ≥ 50% luminal diameter stenosis. Diabetic patients had more adverse risk factors for coronary artery disease, yet there was no significant difference in the prevalence of coronary artery disease between the diabetic and non-diabetic patients (67% vs. 55%, p = 0.15), or in the number of affected coronary artery segments (2.0 vs. 1.4, p = 0.05). Triple vessel coronary artery disease was however, significantly more common among the diabetic subjects (27% vs. 12%, p = 0.005). Non-diabetic patients with end stage renal disease also have a high prevalence of coronary artery disease and may merit as careful investigation of their coronary status as their diabetic counterparts.     

Changes in the clinical condition of haemodialysis patients

The characteristics of the dialytic population have substantially changed over the past 30 years, becoming older and with a greater number of coexisting diseases. The considerable evolution in treatment modalities has lead to a significant increase in the efficacy and tolerability of dialysis. However, physicians have to deal with illnesses in long term dialysis survivors that may be a consequence of inadequate renal replacement therapy rather than of the dialysis procedure per se. Cardiovascular diseases are the leading cause of death and, although many of the risk factors are the same as in the general population (i.e. hypertension), some appear to be specific to CRF (i.e. hyperparathyroidism, anaemia). Age is the most important demographic factor associated with increased mortality. The increasing incidence of ESRD diabetic patients, as well as malnutrition, also contribute to higher mortality in RRT. The therapeutic answer to a worsening in clinical condition is adequate medical care (starting in the conservative phase), with particular attention being given to correcting anaemia, hypertension, volume overload and hyperparathyroidism, and preventing malnutrition. Treatment modalities also play a crucial role. Data suggest that adequate dialytic dose (and possibly time) can reduce morbidity and mortality, and on-line sodium and potassium modelling can improve intradialytic cardiovascular stability and reduce arrhythmias. Long-term treatment with synthetic high-flux membranes may confer some beneficial effect on beta2-m amyloidosis-related morbidity and may also reduce mortality. Family and social support greatly affect the quality of life of the patients. However technologically advanced, no procedure can succeed unless it is performed in the context of humanised health care directed towards patient needs.     

High Risk Ratio on Mortality and Characteristics of Malignancies in Dialysis Patients

A questionnaire study was done in order to clarify the risk ratios on the mortality of malignancy and the characteristics of malignancies in dialysis patients. The risk ratios were 4.2 times in males and 7.5 times in females greater than those among the age adjusted general population respectively. The average interval from the first dialysis to the clinical onset of malignant disease was 12 months. About a half of the patients died within 3 months. Frequencies of death in colon cancer, especially rectum, uterus and liver were higher in dialysis patients. Dialysis patients died of malignancies belonged to the older group of the dialysis patient population, however they were younger comparing with those died of malignancies in the general population.     

Cardiac complications of end-stage renal disease

Cardiovascular disease is the leading cause of death in patients receiving dialysis. This is attributed in part to the shared risk factors of cardiovascular disease and end-stage renal disease. The risk factors for coronary artery disease include the classic cardiac risk factors of diabetes mellitus, hypertension, dyslipidemia, and smoking. Also in this population, hyperparathyroidism, hypoalbuminemia, hyperhomocysteinemia, elevated levels of apolipoprotein (a), and the type of dialysis membrane may play a role. Management begins with risk factor modification and medical therapy including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and lipid-lowering agents. Revascularization is often important, and coronary artery bypass grafting appears to be preferable to percutaneous transluminal coronary angioplasty. This is especially true for those with multivessel disease, impaired left ventricular function, severe symptoms, or ischemia. Congestive heart failure is another common problem in dialysis patients. The management includes correction of underlying abnormalities, optimal dialysis, and medical therapy. Data obtained from the general population indicate obvious benefits from ACE inhibitors and beta blockers, and these agents would be considered the therapies of choice. Erythropoetin is also an essential component of therapy, but the ideal hemoglobin concentration has yet to be determined. Peritoneal dialysis may be helpful in severe cases of heart failure. Pericarditis is seen in less than 10% of dialysis patients and is best diagnosed by clinical examination and echocardiography. Intensive dialysis is often the best initial therapy. Pericardiocentesis is reserved for the setting of pericardial tamponade, but a pericardial window is more definitive.     

Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge

The increasing awareness of the high prevalence of cardiovascular disease (CVD) in the dialysis population has led clinical nephrologists and researchers to focus their attention on processes and factors that are present in patients prior to dialysis. It is clear that many of the risk factors for kidney disease and cardiovascular disease are similar: This may account for the high prevalence of CVD within the dialysis population. However, it is evident that there are unique risk factors for CVD that are present in patients with chronic kidney disease (CKD). These unique uremia-related risk factors for CVD include anemia, hyperparathyroidism, abnormalities of mineral metabolism, and acidosis. Of note, the association of anemia, or lower levels of hemoglobin, have been consistently described in all populations with kidney disease. Left ventricular hypertrophy has long been known as an independent risk factor for death and CV events, in both the dialysis and general populations. There have been accumulating data that LVH and left ventricular (LV) growth occur prior to dialysis in patients with kidney disease, and that the prevalence of LVH in that group of patients is caused by, conventional risk factors for LVH (e.g., hypertension) as well as nonconventional risk factors such as anemia.     

Physical functional status and factors contributing to disability in Japanese chronic dialysis patients

SUMMARY: Four hundred and eight non-hospitalized chronic dialysis patients were surveyed to evaluate functional status by the modified Karnofsky Performance Scale (KPS), and the correlation of clinical variables with functional status and the factors contributing to disability were assessed. Sixty-seven patients (16.4%) had a score less than 75, which indicated limited daily activities inside the home. the percentages of diabetic patients significantly increased in those with a low KPS level (P<0.0001). the mean KPS was significantly lower in the older age group, however there were no significant differences in the mean KPS among groups with different duration of dialysis except for between non-diabetic patients less than 5 years and those longer than 20 years. Serum urea nitrogen, serum creatinine, serum albumin and intra-dialytic weight gain tended to be lower in patients with a low KPS level. Visual impairment and muscle weakness of the extremities was the most common factor contributing to disability in diabetic patients and non-diabetic patients scoring less than 75, respectively. In addition, osteoarticular impairment was characteristically associated with disability in non-diabetic patients. In conclusion, although a great number of chronic dialysis patients maintain a good functional status, there is a small percentage of patients with poor physical activities. the aetiology of poor functional status is multifactorial, and visual impairment for diabetic patients, muscle weakness and osteoarticular impairment for non-diabetic patients require special attention and efforts to ameliorate various factors which negatively affect functional ability in these patients are needed.     

Outcomes of stage 1–5 chronic kidney disease in Mainland China

Objective: This study aims to quantify and compare the risks of death and end stage renal disease (ESRD) in a prospective cohort of patients with chronic kidney disease (CKD) stages 1–5 under renal management clinic at Peking University Third Hospital and to evaluate the risk factors associated with these two outcomes. Method: This was a prospective cohort study. Finally, 1076 patients at CKD stage 1–5 short of dialysis were recruited from renal management clinic. Patients were monitored for up to Dec, 2011 or until ESRD and death. Glomerular filtration rate was estimated (eGFR) according to the using the CKD Epidemiology Collaboration (CKD-EPI) formula. Results: At the end of follow-up, 111 patients (10.1%) developed ESRD (initiated dialysis or kidney transplantation (ESRD)) and 24 patients (2.2%) had died. There were more ESRD occurrence rate in patients with baseline diabetic nephropathy, lower eGFR, hemoglobin <100?g/L and 24?h urinary protein excretion ≥3.0?g. By multivariate Cox regression model, having heavy proteinuria and CKD stage were the risk factors of ESRD. For all-cause mortality, the most common cause was cardiovascular disease, followed by infectious disease and cancer. But we failed to conclude any significant variable as risk factors for mortality in multivariate analysis. Conclusions: Our study indicated that baseline diabetic nephropathy, lower hemoglobin level, lower baseline GFR and heavy proteinuria were the risk factors of ESRD. In this CKD cohort, patients were more likely to develop ESRD than mortality, and cardiovascular mortality was the leading cause of death, and then followed by infectious diseases and cancer in this population.     

Effect of the duration of dialysis on survival in a cohort of chronic haemodialysis patients.

BACKGROUND: Atherosclerosis and vascular calcification are common in chronic haemodialysis (HD) patients, and usually progress with time. Whether the length of dialysis treatment in chronic HD patients is a significant independent risk factor of death is not clear. METHODS: A cohort of chronic HD patients from the Okinawa Dialysis Study, n=1243 (720 men, 523 women), was followed from January 1991 to December 2000, and their survival rates were compared against the duration of HD, which was calculated in months from the start of dialysis therapy to January 1991. A Cox proportional hazards regression analysis was done to examine the influence of the duration of dialysis on survival, after adjusting for other factors such as age, sex, serum albumin concentration and diastolic blood pressure. The hazards ratio and 95% confidence interval (CI) were calculated in both diabetic and non-diabetic patients. RESULTS: The mean duration of dialysis was 61.9 months and ranged from 1 to 233 months. The numbers of patients who died, underwent renal transplantation or were transferred outside Okinawa were 568 (45.7%), 61 (4.9%) and 14 (1.1%), respectively, during the study. The hazards ratio (95% CI) was 1.002 (1.000-1.004, P=0.0245) for non-diabetic patients and 1.006 (1.001-1.011, P=0.0214) for diabetic patients, suggesting that the longer the duration of dialysis, the greater the risk of death. CONCLUSIONS: This study shows that prolonged dialysis is a significant predictor of death in chronic HD patients, in particular diabetic patients. Whether this is related to the progression of the atherosclerotic process or to uraemic conditions remains to be shown.     

Renal Replacement Therapy in Patients with Diabetic Nephropathy, 1980-1985: Report from the European Dialysis and Transplant Association Registry

Diabetic nephropathy, a rarely listed cause of end-stage renalfailure (ESRF) among patients starting renal replacement therapy(RRT) in the early seventies, has progressively gained in importanceand become one of the major reasons for the continuous growthof the patient population on RRT in most European countries.Amongst new patients commencing RRT in 1985, the acceptancerate varied between 3 and 12 per million population for typeI diabetes mellitus and between one and four per million populationfor type II diabetes mellitus. Nordic countries, particularlySweden and Finland, had the highest acceptance rate of youngpatients with type I diabetes mellitus whose median ages were38–42 years. In most central and southern European countriesthe median age of patients with type I diabetes mellitus variedbetween 50 and 58 years. The high number of young patients withtype I diabetes mellitus and ESRF in Nordic countries pointto a different natural history of this disease. It cannot beexcluded, however, that the higher median age in other countriesmight result from doctors mistakenly diagnosing type I diseasein patients with type II disease who need insulin treatment.Patients with type II diabetes mellitus had a similar age distributionat start of RRT throughout Europe and their median ages clusteredaround 60 years in most countries. The contribution of haemodialysis, peritoneal dialysis and renaltransplantation was analysed for diabetic compared to non-diabeticESRF. Despite large geographical differences in the proportionaluse of methods of treatment, a general trend to apply CAPD morefrequently in diabetic as compared to non-diabetic patientswas observed, and this was true for countries with both predominanthaemodialysis and predominant transplant programmes. Transplantationwithout prior dialysis was performed in 17% of Swedish and 30%of Norwegian patients with type I diabetes mellitus. In order to better explain the high mortality of patients withdiabetic ESRF, the proportional distribution of causes of deathwas analysed. Myocardial ischaemia and infarction was confirmedto be the leading cause of death in patients with diabetes mellituson RRT. The coronary death rate was estimated to be 10 timesgreater in young patients with type I diabetes mellitus as comparedto their non-diabetic counterparts. Other cardiovascular aswell as infectious causes were recorded in a similar proportionof deaths in diabetics as in non-diabetics. Cancer deaths, however,appeared to be definitely less frequent in patients on RRT dueto diabetic nephropathy.     

Preventive medical screening is not appropriate for many chronic dialysis patients

Establishing guidelines for the appropriate preventive medical care for chronic dialysis patients requires consideration of many factors. These include the population's underlying risk factors and expected survival, the effectiveness of screening procedures in improving the duration and/or quality of life, and the potential for renal transplantation. Although many nephrologists order and direct routine cancer screening in their dialysis patients, recent studies suggest such screening is not cost effective. Cardiovascular disease is the leading cause of death among end-stage renal disease (ESRD) patients and peripheral vascular disease is a leading cause of morbidity among dialysis patients, but even less is known about the cost-effectiveness of screening for peripheral vascular and cardiovascular disease risks in ESRD patients. Despite a recently reported overall standardized cancer incidence of 1.18 in dialysis patients compared with normal populations, the shortened expected survival of dialysis patients argues against routine cancer screening in this population. Dialysis units and nephrologists should focus cancer screening on individual patients and include specific cancer risk as well as expected survival assessments and transplant candidacy in their decisions to screen a patient for cancer. Routine cancer screening of all dialysis patients is not indicated. Additional study of the benefits and cost-effectiveness of screening ESRD patients for cardiovascular and peripheral vascular disease risk factors is needed.     

糖尿病与非糖尿病血液透析患者透析期间心电图变化对照研究

目的 观察伴或不伴糖尿病的维持性血液透析(maintenance hemodialysis,MHD)患者透析期间心电图变化情况.方法 选择新乡市血液净化中心100例MHD患者,分为糖尿病组(41例)和非糖尿病组(59例),分析两组患者血液透析期间心电图变化情况.结果 糖尿病组年龄显著高于非糖尿病组(P＜0.05),透析后总钙水平显著低于非糖尿病组(P＜0.05),透析中心律失常发生率显著高于非糖尿病组(P＜0.05),其中糖尿病组室上性早搏发生率显著高于非糖尿病组(P＜0.05).结论 糖尿病组透中心律失常发生率显著高于非糖尿病组,其中以室上性早搏发生率最明显,与年龄及透析中血钙下降程度相关.